At the end of November 2023, AOPell Pharmaceuticals GmbH (AOP Health), a Vienna, Austria-based pharmaceutical company, received authorization from Health Canada for its ultra-short-acting, highly cardioselective 1-receptor blocker. This drug is used in intensive care,** atrial fibrillation, atrial flutter (supraventricular tachycardia), and uncompensated sinus tachycardia, i.e., a rapid heartbeat in the absence of an identifiable cause. The authorization gives certain critical care patients access to additional** options, while also opening the door to the North American market for AOPhealth.
Landerol has been authorized in the European Union and has been presented to the Canadian medical community at several international medical conferences. In Canada, landilol is only available in hospitals.
Martin Steinhart, Chief Executive Officer of AOP Health, said: "The approval of landilol in Canada is a great success for us and demonstrates how we have expanded our choice for intensive care patients through our R&D activities. ”
Local dealers.
Landilol will be available for sale through local partner Trimedic Therapeutics Inc.
CSILLA REPAS, Director of Corporate Alliances at AOP Health, said, "Trimentherapeutics IncA well-known player in the Canadian healthcare industry and an expert in the field of critical care, with the expertise needed to successfully enter the market. We are excited to work with Trimetherapeutics IncThis is a strong partner to accomplish this important task. ”
About supraventricular tachycardia.
Supraventricular tachycardia (including atrial fibrillation and atrial flutter) may occur regardless of whether the patient has a history of heart disease. Immediate medical attention is required due to the fact that its symptoms impair the function of the heart, which can lead to acute problems in the cardiovascular system. Compared to other highly selective 1-blockers, AOP Health's ultra-short-acting blockers are characterized by a faster onset of action, rapid lowering of heart rate, and no significant reduction in blood pressure. This intravenous receptor blocker is limited to use in acute situations and emergencies and is not indicated for chronic arrhythmias.
About AOP Health
AOP Health Group is made up of a number of companies, including AOP Health, an AOP rare disease drug based in Vienna, Austria). AOP HealthGroup is a pioneer in the integration of rare diseases and critical care in Europe**. Over the past 25 years, the Group has developed into a full-fledged integrated solutions provider. Headquartered in Vienna, the Group has subsidiaries and representative offices in Europe and the Middle East, as well as a global network of partners. Its "needs, science, trust." science. trust.The Group's success is based on a sustained high level of investment in R&D and a highly consistent and pragmatic approach to meeting the needs of all stakeholders, especially patients and their families, as well as healthcare professionals.